Tirzepatide Dosing Protocol
Tirzepatide is a dual GIP/GLP-1 receptor agonist engaging both incretin pathways. The SURPASS and SURMOUNT trial programs demonstrated significant efficacy in glycemic control and weight reduction with structured titration.
Key Points
Step-by-Step Guide
Start at 2.5 mg Weekly
Begin with 2.5 mg subcutaneously once weekly for 4 weeks. This dose is for GI adaptation rather than therapeutic effect.
Escalate to 5 mg
Increase to 5 mg weekly at week 5. This is the first therapeutically active dose. Maintain for 4 weeks.
Escalate to 7.5 mg
Increase to 7.5 mg at week 9 if additional efficacy is desired and 5 mg is well tolerated.
Escalate to 10 mg
At week 13, increase to 10 mg weekly. Many subjects achieve target endpoints at this mid-range dose.
Maximum Escalation
If needed, escalate to 12.5 mg at week 17 and 15 mg at week 21. The 15 mg dose showed the greatest weight reduction but higher GI side effects.
Monitor Dual-Pathway Markers
Track glucose, insulin, GIP, GLP-1 activity, body composition, and lipid profiles for this dual-agonist.
Warnings & Precautions
- !Never skip titration steps—GI events are dose-dependent.
- !Not recommended for subjects with pancreatitis history.
- !Monitor thyroid function; boxed warning for thyroid C-cell tumors in rodents.
- !Dose adjustments needed with co-administered insulin or sulfonylureas.
Frequently Asked Questions
How does tirzepatide differ from semaglutide?
Tirzepatide targets both GIP and GLP-1 receptors (dual agonist) while semaglutide targets only GLP-1. Tirzepatide uses milligram dosing (2.5-15 mg) with more dose steps.
What is the most effective tirzepatide dose?
In SURMOUNT-1, 15 mg produced the greatest weight loss (22.5%). However, 10 mg offered a favorable balance of efficacy and tolerability.
Can escalation be slowed?
Yes. If GI side effects are significant, maintaining the current dose for an extra 4 weeks before escalating is a common modification.